Eloxx Pharmaceuticals, Inc. (ELOX): Net Income
-$6.00M
Year ended 2025-12-31
-$10.65M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.00M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$3.14M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$17.05M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$36.06M | n/m | 2023-03-31, From 2022-01-01 |
| 2021-12-31 | -$66.73M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$34.58M | n/m | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | -$50.87M | n/m | 2022-03-30, From 2019-01-01 |
| 2018-12-31 | -$47.19M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | -$21.21M | n/m | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | -$9.85M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$6.41M | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2014-06-30 and 2015-12-31. | |||
| 2014-06-30 | -$9.23M | n/m | 2016-10-13, From 2013-07-01 |
| 2013-06-30 | -$6.12M | n/m | 2015-10-09, From 2012-07-01 |
| 2012-06-30 | -$5.07M | n/m | 2014-09-29, From 2011-07-01 |
| 2011-06-30 | -$7.27M | n/m | 2013-09-11, From 2010-07-01 |
| 2010-06-30 | -$13.38M | n/m | 2013-09-11, From 2009-07-01 |
| 2009-06-30 | -$5.73M | n/m | 2013-09-11, From 2008-07-01 |
| 2008-06-30 | -$4.60M | n/m | 2013-09-11, From 2007-07-01 |
| 2007-06-30 | -$3.25M | n/m | 2013-09-11, From 2006-07-01 |
| 2006-06-30 | -$3.31M | n/m | 2013-09-11, From 2005-07-01 |
| 2005-06-30 | -$2.98M | n/m | 2013-09-11, From 2004-07-01 |
| 2004-06-30 | -$3.73M | n/m | 2013-09-11, From 2003-07-01 |
| 2003-06-30 | -$2.78M | n/m | 2013-09-11, From 2002-07-01 |
| 2002-06-30 | -$3.02M | n/m | 2013-09-11, From 2001-07-01 |
| 2001-06-30 | -$2.03M | n/m | 2013-09-11, From 2000-07-01 |
| 2000-06-30 | -$3.35M | n/m | 2013-09-11, From 1999-07-01 |
| 1999-06-30 | -$1.17M | n/a | 2013-09-11, From 1998-07-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | -$6.00M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $16.33M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $7.71B | +88.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $48.89M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$1.18M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $181.86M | +147.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.29B | -20.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$63.53M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $8.51B | n/m |
Compare ELOX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗